Persistence on Oral HIV Pre-Exposure Prophylaxis Among Key Populations at a Centre in Buenos Aires: A Survival Analysis of a Real-World Cohort
Abstract
Introduction: Although HIV pre-exposure prophylaxis (PrEP) has been rapidly scaled up in Argentina to reach key populations with high HIV burden, evidence on real-world persistence is lacking. Understanding who remains engaged in care, and why others discontinue, is essential to ensure the effectiveness of PrEP. This study evaluated oral PrEP persistence and identified demographic and behavioural factors associated with discontinuation in a cohort of individuals initiating PrEP in Buenos Aires.
Methods: We performed a retrospective cohort study including all users initiating daily or event-driven oral PrEP at our centre between September 2021 and July 2025. The cohort consisted of transgender women (TGW), men who have sex with men (MSM) and cisgender women engaged in sex work (cSW), in line with national PrEP guidelines. Persistence on PrEP was defined as the time to first discontinuation (TFD), either self-reported or estimated as the date when the last dispensed PrEP pill would have been exhausted if taken daily. Categories for discontinuation included participant-reported causes and loss to follow-up (LTFU). TFD was evaluated using survival analysis. Cox proportional hazards models were fitted to examine associations between TFD and sociodemographic and behavioural factors.
Results: Overall, 970 individuals initiated PrEP: 69% MSM, 24% TGW and 6% cSW. Median age was 31 years (IQR 26-36). During follow-up, 447 participants (46%) discontinued PrEP. Persistence declined…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 970 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.